An Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel, in Combination With Paclitaxel, or in Combination With Anastrozole in Subjects With Selected Solid Tumors

Trial Profile

An Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel, in Combination With Paclitaxel, or in Combination With Anastrozole in Subjects With Selected Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Miransertib (Primary) ; Anastrozole; Carboplatin; Paclitaxel
  • Indications Endometrial cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors ArQule
  • Most Recent Events

    • 12 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 12 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 02 Jun 2017 Results (n=13), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top